文献速递前列腺癌

177Lu-PSMA放射性配体治疗转移性去势抵抗性前列腺癌的系统评价与荟萃分析

A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2021-04-08

该系统评价与荟萃分析纳入24项研究共1192例转移性去势抵抗性前列腺癌患者,评估177Lu-PSMA放射性配体治疗(PRLT)的疗效与毒性。3/4级毒性不常见,贫血最高为0.08(0.05-0.12)。

核心结论

  • PRLT在转移性去势抵抗性前列腺癌中显示出较高的PSA应答率和较低的严重毒性发生率,具有潜在应用前景。

研究设计与样本

  • 系统检索PubMed/Medline(截至2019年2月18日),最终纳入24项研究共1192例患者。
  • 采用单比例荟萃分析,并比较177Lu-PSMA-617与177Lu-PSMA-I&T的疗效与毒性。

关键数值与推荐

  • PSA应答定义为血清PSA较基线下降≥50%,且治疗与PSA测量间隔至少8周。
  • 毒性分级采用不良事件通用术语标准(CTCAE)。

临床怎么用

  • PRLT可用于转移性去势抵抗性前列腺癌的治疗选择,尤其关注PSA应答情况。
  • 治疗前应评估患者贫血等基线情况,治疗中监测3/4级毒性。
  • 超过1个周期的PRLT可能与更高的PSA应答率相关。

局限性

  • 纳入研究间存在显著异质性,尤其在任何级别毒性组。
  • 研究多为回顾性,需前瞻性研究进一步验证。
  • 检索截止至2019年2月,后续研究未纳入。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Castration-resistant prostate cancer (CRPC) treatment is an evolving challenge. Prostate-specific membrane antigen (PSMA)-targeted endoradiotherapy/radioligand therapy (PRLT) with small-molecule, urea-based agents labeled with the β-particle-emitting radionuclide lutetium-177 (177Lu) is a promising new approach. OBJECTIVE: In this systematic review and meta-analysis, we evaluated the efficacy and toxicity of PRLT. EVIDENCE ACQUISITION: A systematic search was performed in PubMed/Medline (last updated February 18, 2019). A total of 250 studies were reviewed, and 24 studies with 1192 patients were included in the analysis. Proportions of patients with ≥50% serum prostate-specific antigen (PSA) decrease, any PSA decrease, and any PSA increase were extracted. Proportions of patients showing any grade toxicity and those with grade 3/4 toxicities based on Common Terminology Criteria for Adverse Events (CTCAE) grading were extracted from manuscripts. Overall survival and progression-free survival were evaluated. A meta-analysis of single proportions was carried out. Furthermore, we compared the two most common PRLT agents, 177Lu-PSMA with 177Lu-PSMA-I&T, for effectiveness and toxicity. EVIDENCE SYNTHESIS: Among the 24 included studies, 20 included data on 177Lu-PSMA-617, three included data on 177Lu-PSMA-I&T, and one study had aggregated data for 177Lu-PSMA-617 and 177Lu-PSMA-I&T. The estimated proportion of 177Lu-PSMA-617-treated patients who showed a serum PSA decrease of ≥50% with at least an 8-wk interval between therapy and PSA measurement was 0.44 (0.39; 0.50). Therapy with 177Lu-PSMA-I&T demonstrated an estimated proportion of patients with ≥50% PSA reduction to be 0.36 (0.26; 0.47). The aggregate results for men treated with more than one cycle of any kind of PRLT showed an estimated proportion of 0.46 (0.41; 0.51) for PSA response ≥50%. Regarding aggregate data from all of the PRLT agents, we found that grade 3 and 4 toxicities were uncommon, with estimated proportions from 0.01 (0.00;0.04) for nausea, fatigue, diarrhea, and elevated aspartate transaminase up to 0.08 (0.05; 0.12) for anemia. There was considerable heterogeneity among the studies in the "any-grade toxicity" groups. Meta-regression showed that more than one cycle of PRLT is associated with a greater proportion of patients with ≥50% PSA reduction. Overall survival according to pooled hazard ratios (HRs) for any PSA decline was 0.29 (0.18; 0.46), and for >50% PSA reduction was 0.67 (0.43; 1.07). Progression-free survival according to a pooled HR of >50% PSA reduction was 0.53 (0.32; 0.86). CONCLUSIONS: The relatively high number of PSA responders alongside the low rate of severe toxicity reflects the potentially promising role of PRLT in treating CRPC. The ultimate utility of this treatment modality will become clearer as multiple prospective studies continue to accrue. In the interim, this systematic review and meta-analysis can serve as a compendium of effectiveness and adverse events associated with PRLT for treating clinicians. PATIENT SUMMARY: Prostate-specific membrane antigen-targeted endoradiotherapy/radioligand therapy (PRLT) is associated with ≥50% reduction in prostate-specific antigen level in a large number of patients and a low rate of toxicity, reflecting its potential in treating castration-resistant prostate cancer. This systematic review and meta-analysis presents as a compendium of the effectiveness and adverse events related to PRLT for treating clinicians.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sadaghiani MS, Sheikhbahaei S, Werner RA, et al. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Eur Urol. 2021. PMID: 33840558. doi:10.1016/j.eururo.2021.03.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。